Our goal was to compare direct and indirect medical costs and quality of life associated with inpatient vs outpatient autologous hematopoietic stem cell transplantation (AuHSCT). Twenty-one sequential outpatients and 26 inpatients were enrolled on this prospective trial. All candidates for AuHSCT were screened for eligibility for outpatient transplantation. Patients with either breast cancer or hematologic malignancy, insurance coverage for the outpatient procedure, one to three caregivers available to provide 24 h coverage, and no significant comorbidities were eligible to participate. Patients without caregivers or insurance coverage for outpatient transplant were accrued to the study in a consecutive manner as inpatient controls, based on willingness to participate in the quality of life portion of the study and to permit review of their hospital and billing records. Approximately half of all 139 prospective outpatient candidates were ineligible because they lacked a caregiver. Most commonly, the patient without a caregiver was single or widowed or their family and friends were needed to provide childcare. Most caregivers were college educated from families with incomes greater than $80 000. Indirect costs to the caregivers totaled a median of $2520 (range $684-$4508), with the majority attributed to lost 'opportunity costs'. Overall, there were significant differences in the total costs of treatment for inpatient vs outpatient AuHSCT ($40 985 vs $29 210, P Ͻ 0.01)). In general, no significant differences were detected between inpatient and outpatient scores on quality of life measures. Although significant cost savings were associated with outpatient transplantation, this approach was applicable to only half of our otherwise eligible candidates because of a lack of caregivers. The financial burden associated with the caretaking role may underlie this finding.
Concerns over the cost of high-dose therapy and hematopoietic stem cell transplantation (HSCT) have led programs to seek alternatives to the traditional inpatient stay. The rapid engraftment associated with the use of mobilized peripheral blood progenitor cell (PBPC) autografts and growth factor administration, as well as new antiemetics, have made outpatient HSCT possible, with family members and friends assuming patient care responsibilities. 1 A growing number of studies have demonstrated reductions in the length of hospital stay without compromising outcome. [2] [3] [4] [5] [6] [7] [8] A reduction in direct medical costs for outpatient HSCT has been demonstrated in some series, fueling enthusiasm for this approach. 2, 4, 7, 9, 10 There is little information, however, on the total costs of transplantation including nonmedical and out-of-pocket costs. 7 It is possible that the cost savings are at least in part cost shifting from the insurer to the patient's family and caregivers.
Outpatient transplantation requires that the patient have one or more caregivers to provide care that will not be provided in the outpatient transplant facility or by homehealth care nurses. How often lack of a caregiver prevents patients from participating in outpatient transplant programs has not been well established. In Meisenberg et al's series, 3 17% of patients offered outpatient transplant declined because they lacked an available, appropriate caregiver. Of those choosing inpatient care, 80% of patients did so because they had no caregiver. The caregiver's financial burden -actual or perceived -may have been overlooked or substantially undervalued.
In the context of a prospective analysis comparing the total societal costs associated with outpatient vs inpatient AuHSCT, we screened sequential patients who presented to the Northwestern University/Northwestern Memorial Hospital Transplant Program for participation in the outpatient program. We were surprised to find that nearly half of the screened patients were unable to participate because they lacked a caregiver(s). To fully quantify the indirect costs associated with the outpatient procedure, we collected data on costs related to the caregiver's role. Although outpatient transplantation may result in significant savings to insurers, the shift in caretaking responsibility to family and friends and lost opportunity costs for the caregiver may limit its applicability.
Patients and methods

Patient eligibility
All candidates for AuHSCT presenting to the Northwestern Memorial Hospital/Northwestern University transplant program were screened for eligibility for outpatient transplantation. Requirements included a diagnosis of breast cancer or hematologic malignancy and insurance coverage for the outpatient procedure (including the cost of the outpatient apartment). Patients judged to have significant comorbidities such as diabetes mellitus or a history of coronary artery disease, which in the opinion of the stem cell transplant team would qualify them as high-risk for the procedure, were excluded. To participate in outpatient AuHSCT, 24 h caregiver coverage was required. Because of the necessary extensive individual training, the number of caregivers was limited to a maximum of three. Potential caregivers and patients were required to be free of psychosocial issues that might prevent them from being compliant with the program. Each patient and caregiver was required to undergo psychosocial screening conducted by a psychiatric nurse experienced in the assessment of patients prior to transplantation. Caregivers were expected to reside with patients 24 h/day, 7 days/week in a residential facility maintained by the hospital. Caregivers were to assist the patient with activities of daily living, to escort the patient to the hospital daily, to administer and assure compliance with medications (oral, intravenous and injectable), record vital signs, monitor intake and output, report adverse events, and to complete a quality of life questionnaire and cost diary.
Patients without caregivers or insurance coverage for outpatient transplant were accrued to the study in a consecutive manner as inpatient controls, based on willingness to participate in the quality of life portion of the investigation and to permit review of their hospital and billing records. An attempt was made to provide a similar number of controls for each disease group. Patients ineligible for outpatient transplantation because of comorbid illness or psychiatric issues that made them high-risk for transplant, were not enrolled as inpatient controls.
This study was approved by our institutional review board (IRB), and informed consent was obtained from both patients and caregivers. Both inpatients and outpatients were treated according to the same disease-specific IRB approved transplant protocols for which separate consent was obtained.
Outpatient clinical procedures
Patients and their families were educated regarding the role of the caregiver. Each patient and caregiver(s) was provided with an educational binder complete with instructions on food preparation, dietary guidelines, patient care (taking vital signs, quantitating intake and output), neutropenic precautions, signs and symptoms of infection and data collection. The nurse clinician met with the caregivers individually for training. The number of sessions varied according to patient and caregiver need.
Outpatients and their caregivers were housed in a residential facility specially equipped for HSCT patients, in close proximity to the hospital. They were evaluated daily (except for occasional Sundays), in the Northwestern Memorial Hospital Clinical Research Center by transplant physicians. Home healthcare nurses facilitated these visits by drawing blood early in the morning for daily complete blood counts and blood chemistries (and twice weekly liver function tests) and by providing fluids and medications during evening hours, when necessary. Patient and caregiver compliance with outpatient procedures was assessed daily through review of records maintained by the caregiver. Outpatients received prophylactic antibiotics, including antibacterial (ciprofloxacin and rifampin), antifungal (fluconazole or alternate day low-dose amphotericin for patients with hematologic malignancies) and antiviral (acyclovir) agents. For Pneumocystis carinii prophylaxis, patients received aerosolized pentamidine monthly, or trimethoprim/sulfamethoxazole double strength, three times weekly if there was reason to believe that pentamidine distribution would be inadequate. Six of the 21 outpatients received their chemotherapy as inpatients due to logistic concerns (such as stability of the agents or chemotherapy volume), and were discharged to the outpatient residential facility after completion of their chemotherapy. Reinfusion of the autograft occurred in the Clinical Research Center on day 0. In the event of fever, patients were admitted to the inpatient unit. After cultures of blood, urine and any other potentially infected site had been obtained along with a chest X-ray, they were started on broad-spectrum antibiotics; the same antibiotic regimen was prescribed for both inpatients and outpatients admitted with fever (Zosyn (Wyeth Pharmaceuticals, Collegeville, PA, USA) and amikacin). At 24 h, those who had negative blood cultures and chest X-rays, and were otherwise judged to be medically stable were discharged to the outpatient facility on once daily intravenous antibiotics (ceftriaxone and amikacin).
Total parenteral nutrition was administered to the outpatients when necessary. A log of daily intake was maintained by the patient and caregiver. Discharge criteria were identical for inpatients and outpatients. To be eligible for discharge, patients were required to have an absolute neutrophil count over 1000/l and to be afebrile off empiric antibiotics for a minimum of 24 h. Patients with positive cultures were permitted to receive intravenous antibiotics at home to complete a planned course if surveillance cultures had been negative. Patients were discharged only if platelet transfusions were required no more often than every 48 h.
Inpatient procedures
Transplant patients with either breast cancer or hematologic malignancies who were ineligible for the outpatient pro-gram by virtue of a lack of caregiver(s) or insurance coverage, but were otherwise eligible for the outpatient program, were recruited as inpatient controls. Hence, high-risk patients with complicating medical illness were not eligible as controls. Informed consent was obtained from inpatients who agreed to complete quality of life questionnaires on a weekly basis and to permit analysis of their medical bills and hospital charts. A uniform prophylactic antibiotic regimen was not required by protocol for the inpatients. Instead, the transplant program's standard regimen at the time was prescribed. Inpatients were treated with prophylactic fluconazole or low-dose amphotericin (for hematologic malignancy patients), and acyclovir or valacyclovir. Either aerosolized pentamidine or trimethoprim/ sulfamethoxazole double strength was administered to provide Pneumocystis carinii prophylaxis. A fluoroquinolone was not prescribed for inpatients because of hospital policies designed to reduce the emergence of antibiotic resistance. Inpatients received both their chemotherapy and their post-transplant care on the inpatient transplant unit.
Quality of life instruments
Patients completed a 'quality of life' questionnaire on a weekly basis beginning prior to therapy and then weekly until discharge from the in-or outpatient facility. A posttransplant evaluation was obtained during the 5th week post transplant. The following three standardized quality of life measures were administered: (1) the Functional Assessment of Cancer Therapy -Bone Marrow Transplant (FACT-BMT), a 29-item scale used to assess five quality of life domains (physical, social, emotional, functional and relationship with physician, and 12 items related to concerns specific to stem cell transplant; 11 (2) Profile of Mood States Brief Scale (POMS), a 14-item rating scale used to assess negative and positive affect; 12 and (3) the Impact of Events Scale (IES), a 15-item scale used to assess the frequency and severity of intrusive and avoidant thoughts specific to high-dose chemotherapy and autologous stem cell reinfusion. 13 
Data collection
New transplant candidates were screened for eligibility for outpatient transplant by the research nurse coordinator. The nurse coordinator prospectively recorded reasons that one or more caregivers were not available to participate in this program.
Throughout the transplant period, caregivers kept daily diaries to record their out-of-pocket expenses (transportation, meals, personal items, paid or unpaid time off from work, and costs due to their absence from home such as baby sitting, home cleaning, lawn services, etc) and to collect sociodemographic information (including employment status and occupation).
Clinical information for each patient was obtained from specifically designed case report forms, including dates of procedures, age, gender, disease and stage, treatment regimen, hospitalization, and use of supportive care agents. This information was used to verify charges on financial records. Detailed financial records were obtained from hosBone Marrow Transplantation pital bills, physician consult bills, and home health care agency bills (for outpatients only). Data were collected from the beginning of high-dose therapy to discharge from the designated facility. Outpatients were housed in a Northwestern Memorial Hospital-owned dormitory facility at a rate of $100/day. For use of the Clinical Research Center, an hourly rate of $30 was charged, equivalent to the cost of care in our outpatient hematology/oncology clinic.
Data analysis
Demographic and medical characteristics were summarized using percentages, medians, and ranges. Chi square statistics were used to compare percentages, and two-sided Mann-Whitney U statistics were used to compare medians between inpatients and outpatients with P Ͻ 0.05 achieving significance. Charges were converted to costs using department-specific cost to charge ratios. Home health care charges were converted using Medicare cost to charge ratios for the appropriate year of service. Charges for physician fees did not have a cost to charge ratio, and were used as a proxy for costs. Median total costs and costs per department were calculated and compared.
To quantitate the costs of the caregivers' time we evaluated their 'opportunity costs' by equating the cost of caregiving with opportunities forgone to perform this activity. Costs to the caregiver were calculated as the sum of the total out of pocket costs reported in the daily diaries and their estimated 'opportunity costs'. The value of the lost 'opportunity costs' was approximated using the individual's labor market earning per time unit, adjusted regionally for their stated occupation and US Bureau of Labor statistics for the Chicago area. 14, 15 For caregivers who were retired, students or homemakers, the average daily wage of a Chicago area employee, $134.88 ($16.86 hourly), was used. The estimated daily wage was multiplied by the number of days spent with the patient in the outpatient facility.
Analyses were performed to examine possible differences in the quality of life experienced by inpatients and outpatients using quality of life measures at day +7, day +14, and during the 5th week post transplant.
Results
Patient characteristics and eligibility
One hundred and sixty-seven patients with breast cancer or hematologic malignancies were screened for participation in the outpatient program (December 1996 to March 2000). Twenty-eight of these patients either proved ineligible for transplantation (unresponsive disease, poor cardiac or pulmonary function, etc), decided against AuHSCT as a therapeutic option, or were transplanted at another institution. Approximately half of all 139 potential outpatient candidates were ineligible because they lacked a caregiver (Table 1) . Most commonly the patient was single or widowed without an identifiable caregiver, or family or friends were needed for childcare. Four patients were excluded after psychosocial screening. These included one patient with bipolar illness who had had difficulties during Table 2 . The median ages, number of prior regimens, and distribution by gender were similar for inpatients and outpatients. There was a slightly higher proportion of breast cancer patients in the inpatient group (46% vs 33%) and a slightly higher proportion of multiple myeloma patients in the outpatient group (43% vs 27%), although these differences were not significant. For breast cancer patients, the distribution by stage between inpatient and outpatient groups was not significant (P = 0.245).
The same treatment protocols were used for both inpatients and outpatients. These included cyclophosphamide/ 
TBI for hematologic malignancies, high-dose melphalan for multiple myeloma, cyclophosphamide, thiotepa and carboplatin (or paclitaxel) for breast cancer, and etoposide, carboplatin, cyclophosphamide for Hodgkin's disease.
Outpatient caregiver characteristics
The personal characteristics of the 21 individuals who cared for the 21 outpatients are summarized in Table 3 . Notably, half had college or advanced degrees and half had family incomes greater than $80 000. Twelve took leave from some kind of paid employment.
Comparison of resource utilization and clinical outcome
The differences between resource utilization for inpatient and outpatient transplant are summarized in Table 4 . There were no significant differences between the numbers of red cell or platelet transfusions administered to inpatients and outpatients. Outpatient AuHSCT was associated with significantly fewer days of intravenous antibiotics and days in hospital than inpatient AuHSCT. A comparison of the numbers of CD34 + cells/kg contained by the mobilized peripheral blood progenitor cell autografts transplanted on day 0, to inpatients and outpatients showed no difference, and the time to an absolute neutrophil count greater than 500/l was identical for the two groups (Table 5) . Outpatients had fewer days of neutropenic fever than inpatients, but only by one day. There were greater numbers of grade 3 infections among the inpatients, although this did not reach statistical significance.
Median follow-up for all patients was 31 months (range 4-55 months). Kaplan-Meier product limit survival curves were calculated for each group (outpatients and inpatients). There was no significant difference between survival for inpatients vs outpatients (log rank test, P = 0.15). The 3 year survival was 74% for outpatients and 63% for inpatients. There were no deaths on either arm within the first 100 days.
Indirect costs
The indirect costs of outpatient AuHSCT are summarized in Table 6 . Total indirect costs to the outpatient caregivers totaled a median of $2520 (range $684-$4508) during a median stay of 15 days, with the majority attributed to lost opportunity costs.
Total costs
Overall, there were significant differences in the costs of treatment for inpatient vs outpatient AuHSCT (Table 7) . Median total costs, excluding the cost of chemotherapy, were $35 282 (range $26 164-$66 073) for inpatient treatment vs $25 582 (range $12 641-38 437) (P Ͻ 0.01) when costs to the caregiver were included in the outpatient total. Specific areas of significant cost differences included room Lost opportunity cost equates the use of one's time in a given activity (such as caregiving) with the opportunities forgone to perform that activity. b Out-of-pocket expenses for the caregiver include meals, childcare, lawn care, dog walking, parking. c Total indirect costs = total lost opportunity costs + out-of-pocket expenses. costs, pharmacy costs, blood products, diagnostic radiology costs, and supplies/other costs. The differences in major cost drivers, such as room, pharmacy and chemotherapy costs were also compared by disease (Figure 1) . Total costs included indirect costs for outpatients. Breast cancer patients had higher total (excluding chemotherapy) median costs ($39 964 vs $28 613, P Ͻ 0.01) and room costs ($14 094 vs $7914, P Ͻ 0.01) when treated as inpatients; however, pharmacy and chemotherapy costs were similar for inpatients and outpatients ($8698 vs $7695, P = 0.26, and $8265 vs $7567, P = 0.38, respectively). Total cost savings for lymphoma/Hodgkin's disease patients, were not as great as for breast cancer patients, with inpatient transplantation costing $33 665 and outpatient treatment costing $28 773 (P Ͻ 0.01). There were significant differences between inpatient and outpatient treatment in room costs ($14 037 vs $7384, respectively; P Ͻ 0.01), and pharmacy costs ($7543 vs $4876, respectively, P Ͻ 0.01). The greatest cost saving was achieved with multiple myeloma patients Figure 1 Median cost differences by disease. Total costs include room, pharmacy (not including chemotherapy), professional fees, laboratory, blood products, diagnostic radiology, home care, and supplies. *P = Ͻ0.05 and represents the difference between inpatients and outpatients. Indirect costs have been added to the total costs for outpatients. IN = inpatients; OP = outpatients.
($31 695 for inpatient treatment vs $19 188 for outpatient transplant, P Ͻ 0.01). Room costs ($13 314 for inpatients vs $3741 for outpatients, P Ͻ 0.01), and pharmacy costs ($7013 for inpatients vs $2838 for outpatients, P = 0.02) were significantly lower for this group of patients. The greater cost savings associated with outpatient transplant for myeloma patients compared to breast and lymphoma patients is most likely related to the ease with which highdose melphalan can be administered in the outpatient setting, and the limited number of side-effects and rapid engraftment.
If the six outpatients who received their chemotherapy as inpatients are excluded from the analysis, the difference in total costs is still significant ($40 985 vs $24 739; P Ͻ 0.01).
Quality of Life
No significant differences were detected between inpatient and outpatients on the physical, social, emotional and functional subscales and total mean scores of the FACT-BMT, the positive and negative affect mean score of the POMS, and the intrusion and avoidance mean score of the IES. This was true for the day +7 (Figures 2 and 3 ) and day +14 assessments as well as that conducted during the 5th week 
Discussion
High costs associated with HSCT have led to the development of outpatient programs designed specifically to reduce utilization of costly inpatient facilities. Comparative studies including this report have demonstrated the safety of this approach and significant cost-savings, particularly among standard risk patients. [2] [3] [4] [5] [6] [7] [8] [9] Whereas the majority of prior studies have measured direct medical costs, we also studied indirect costs to the caregiver including lost 'opportunity costs' and out-of-pocket expenses. At our institution, outpatient transplantation was associated with approximately $14 000 in savings in direct medical costs, without any decrement in quality of life. However, a median of $2520 in out-of-pocket expenses and lost opportunity costs were incurred by the caregivers. These hidden costs may have discouraged or eliminated potential caregivers, and may account for the fact that over half of our candidates for outpatient transplant lacked caregivers.
Studies from other transplant programs have reported varying degrees of difficulty in recruiting caregivers. Early on in the development of outpatient transplantation, Peters et al 2 noted that 'lack of an appropriate family member or friend to act as an educated caregiver' was a major obstacle to discharging transplant patients to the outpatient setting. At Scripps, Meisenberg et al 3, 9 found that lack of a caregiver limited participation in outpatient transplantation in only 11% of 165 transplants, and in 17% of a second series. Lack of a caregiver was, however, the most common reason patients declined participation in their outpatient program. In contrast, lack of insurance coverage for outpatient transplant was the most frequent barrier to outpatient transplant at Johns Hopkins. 7 Sharma and colleagues 16 from Gaines-ville found that psychological factors including severe anxiety or compliance concerns were the most common issues preventing participation of patients in their outpatient transplant program, while only 12% of potential candidates did not participate because they did not have a caregiver. Similar to our experience, the most common caregiver in the Scripps and Hopkins programs was the patient's spouse or parent. Our caregivers were generally well-educated and well-off, with more than half coming from families with incomes greater than $80 000. These were individuals for whom the out-of-pocket and lost opportunity costs did not constitute a financial hardship. At Johns Hopkins, the annual income of all but one of the 17 caregivers for whom this data was reported was less than $50 000, possibly reflecting differences in the demographics of their program when compared to ours. 17 The majority of patients at Scripps resided at home, which may have increased the availability of family for caregiving activities. Although care at home is practical at many institutions, the use of an outpatient apartment facility is a model that many urban and/or tertiary referral centers have chosen out of necessity. Whether caregivers are permitted to have other responsibilities such as the care of children or elderly family members is an important consideration, and may affect the availability of caregivers as well as the quality of the caregiving.
The estimates of the medical costs of outpatient transplantation from our series may be compared to those reported from other transplant centers. Meisenberg et al 9 demonstrated a reduction in medical costs from $39 700 for total inpatient care of breast cancer and lymphoma patients to $29 400 for outpatient care, which is remarkably similar to the $41 000 and $27 000 cost estimates reported in our study. Similarly, for multiple myeloma patients, Jagannath et al 4 reported $13 000 reduction in costs for outpatient AuHSCT which is similar to the $16 000 in cost savings noted in our study. Whereas Rizzo et al 7 studied both autologous and allogeneic patients, it is harder to compare our findings with his. For patients at low risk of recurrence, a savings of $54 000 resulted from outpatient care, while the care of high risk individuals was equally costly in the two settings. Recognizing the potential for cost shifting rather than cost savings, Rizzo included out-of-pocket costs to the patient (but not caregiver) in calculating total charges and found no difference between inpatients and outpatients in this regard. None of the prior studies reported on actual costs associated with caregiving, although Jagannath et al 4 assumed caregivers lost $100/day in wages, and added this estimate to the total costs. We found that caregivers incurred median costs of $2520, with the majority of these costs being related to lost wages. Although family members or friends often spent long hours at the bedsides of inpatients, their presence was not a requirement for transplant; consequently, their indirect costs were not studied. The potential financial burden to those who declined to participate could not be captured in our study. The only comparison data for these costs to caregivers are from the National Hospice Study, an evaluation of the costs and quality of care for terminally ill cancer patients. 5 This study demonstrated that 60% of caregivers reported a loss of income because of care-related time missed from work, averaging $2582. The median cost to caregivers in our study was Bone Marrow Transplantation similar to the cost of caregiving in the hospice setting and in Jagannath's outpatient stem cell transplant study.
Although outpatient transplantation is generally perceived as providing a superior 'quality of life', there is little scientific evidence supporting this point of view. 1 Patients in the Duke outpatient program reported little or no anxiety, although there was no inpatient group for comparison. 18 One could imagine that anxiety levels might be higher for outpatients who do not have the security associated with the inpatient setting. To assess the 'quality of life' of the patients in our trial, three standardized quality of life measures were administered weekly to both inpatients and outpatients. In this study, we found that the overall quality of life scores were similar between inpatient and outpatient transplant patients. The lone exception was the FACT-BMT subscale on which inpatients reported fewer concerns about the transplant procedure than outpatients. It is likely that ready access to nursing and other healthcare providers in the inpatient transplant setting may have led to fewer transplant-related concerns. The small numbers in our series make it difficult to do subset analysis to identify certain demographic groups that may show a 'quality of life' benefit for outpatient transplant.
The limitations of our study should be acknowledged. Patient enrollment was not based on a randomized design, but on patient/caregiver eligibility and preference, and physician recommendation. This process may have allowed for a degree of selection bias, with the possibility of more severely ill patients or patients receiving more intensive chemotherapy regimens being enrolled as inpatients. There was a larger proportion of breast cancer patients in the inpatient arm and multiple myeloma patients in the outpatient arm, which may have contributed to some of the cost differences between inpatients and outpatients. Whereas cost differences remained when the data were analyzed according to diagnosis and patients were treated on a limited number of disease-specific protocols, differences in treatment regimen/intensity are not likely to underlie the differences in costs between inpatients and outpatients. Although the time to engraftment was identical for inpatients and outpatients, there was a significant difference in the median number of days of neutropenic fever -albeit only 1 dayand the number of days of intravenous antibiotics. These differences are likely to underlie some of the differences in pharmacy costs and to have increased the differences in room costs by prolonging hospitalization. There was a trend towards a greater number of grade 3 or 4 infections (27% inpatient vs 5% outpatient). Once afebrile, outpatients were discharged to the outpatient facility to receive parenteral antibiotics only once daily, rather than the conventional three to four times daily schedule prescribed for the inpatients. This approach is likely to have contributed to the difference in pharmacy costs between inpatients and outpatients. Although all inpatients and outpatients received antiviral and antifungal prophylaxis, institutional infection control policies during the period of this study prevented the use of antibacterial prophylaxis to inpatients on a routine basis. Exposure to healthcare personnel including housestaff may have also contributed to these differences. The extent of the financial benefit associated with outpatient transplant, therefore, may be closely tied to institution-specific policies.
Lack of appropriate caregivers had a significant impact on the number of patients eligible for outpatient transplantation at our medical center. Although demographics unique to our institution and region may account for this finding, we believe that it is likely to be a common occurrence, in part related to the financial burden associated with the role, and requires further investigation. Although outpatient transplantation may result in significant savings to insurers, the shift in caretaking responsibility to family and friends and 'lost opportunity costs' for the caregiver may limit its applicability. Reimbursement of the approximately $160 per day in lost wages and out-of-pocket costs to the caregiver by the insurer may increase the availability of caregivers and the applicability of outpatient transplant. Alternatively, paid caregivers may enable some patients to undergo transplant as outpatients, and still preserve the economic advantage.
